PATENT CLAIM ANALYSIS

Application Number: 16295914
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["514", "662000"]

Abstract:
The invention provides extended release amantadine compositions for once daily administration of amantadine to a subject.

Claim (Index 10):
A method of treating a human subject with Parkinson's disease, comprising orally administering to a human subject with Parkinson's disease once-daily a composition comprising:\n (i) a drug, wherein the drug is an NMDA receptor antagonist or a pharmaceutically acceptable salt thereof; and (ii) at least one excipient; wherein:\n at least 50% of the drug is in an extended release form; \n the composition has an in vitro dissolution profile of between 40% and 60% in 2 hours, between 60% and 80% in 6 hours, and greater than 80% in 8 hours; and \n the daily dose of drug administered to the human subject is between 20 mg to 500 mg.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 99.0
- Lexical Diversity: 1.0625
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12757819', '13284630', '12512701', '13751876', '13536525']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8434130312393224
- 35 USC 102 Novelty (BERT): 0.5723757052900664
- Combined Prediction Score: 0.8163092986443969
- Mean Citation Score: 538.45172
- Max Citation Score: 542.6383
- Similarity Product: 367.09553367404334

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test